Paradoxical bronchoconstriction occurs in 5% of COPD patients treated with beta-2-agonists

African–American patients with COPD are more likely to be affected by therapy-induced bronchoconstriction, study suggests.

African-American male patient with chronic obstructive pulmonary disease

Beta2 agonist drugs are used for their bronchodilatory properties in chronic obstructive pulmonary disease (COPD), yet a paradoxical bronchoconstrictive effect, resulting in respiratory distress, occurs in some people.

The first systematic study of responses to beta2 agonists has identified paradoxical bronchoconstriction in 5% of nearly 10,000 patients with COPD. A paradoxical response was twice as common in African–American patients than in other racial groups, and was also associated with worse respiratory outcomes, including more severe dyspnoea, shorter six-minute walk distance and more frequent severe exacerbations.

“These findings might have implications for the use of beta2 agonists in some patients,” conclude Surya Bhatt, from the University of Alabama in Birmingham, and colleagues writing in The Lancet Respiratory Medicine (online, 10 September 2014).[1]


 [1] Bhatt SP, Wells JM, Kim V et al. Radiological correlates and clinical implications of the paradoxical lung function response to β2 agonists: an observational study. The Lancet Respiratory Medicine. Online 10 September 2014 doi:10.1016/S2213-2600(14)70185-7

Last updated
The Pharmaceutical Journal, PJ, 20 September 2014, Vol 293, No 7828;293(7828):DOI:10.1211/PJ.2014.20066436